Clinical Trial Update: Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cetuximab with platinum and taxane-based chemotherapy followed by avelumab and cetuximab as first-line treatment for recurrent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Cetuximab (cetuximab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer | Phase 2 | Status: RECRUITING